Drug Profile
Research programme: serotonin 3 receptor modulators - Curia
Alternative Names: 5-HT3 receptor antagonists - Curia; 5-HT3 receptor partial agonists - Curia; ALB-137391(a); AMR-SER-67Latest Information Update: 15 Oct 2021
Price :
$50
*
At a glance
- Originator AMRI
- Developer Curia
- Class Benzoxazoles; Indazoles; Indoles
- Mechanism of Action Serotonin 3 receptor antagonists; Serotonin 3 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Irritable bowel syndrome
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for preclinical development in Irritable-bowel-syndrome in USA (PO)
- 09 Sep 2016 AMRI's serotonin 3 receptor modulator programme is still in preclinical development for Irritable bowl syndrome (AMRI pipeline, September 2016)
- 12 Oct 2010 Preclinical development is ongoing in USA